智翔金泰 (688443)

Chongqing Genrix Biopharmaceutical Co., Ltd.

KSH

Tags

SSE 580 IndexLoss-Making StocksInnovative DrugsBroker Heavy PositionsPharmaceutical ManufacturingPharmaceuticals and HealthcareFund Reduction PositionsBiological ProductsBelow IPO PriceSTAR Market 100 IndexSTAR Market Growth IndexSTAR Market Biotechnology IndexTechnology Growth LayerMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 36668.00
  • Circulating A-Shares(W): 11668.00
  • Earnings Per Share(RMB): -0.9100
  • Net Assets Per Share(RMB): 4.8757
  • Operating Revenue(W RMB): 20755.53
  • Total Profit(W RMB): -33259.25
  • **Net Profit Attributable to Parent(W RMB) **: -33259.25
  • Net Profit Growth Rate(%): 39.12
  • Weighted Return on Equity(%): -17.0100
  • Operating Cash Flow Per Share(RMB): -0.7120
  • Undistributed Profit Per Share(RMB): -7.5008
  • Capital Reserve Per Share(RMB): 11.4319

2. Main Business

The main business covers:

  • Research, development, production, and sales of antibody drugs

3. Company Basic Information

  • Company Name: Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd.
  • Listing Date: 2023-06-20
  • Industry: Pharmaceutical Manufacturing
  • Address: Area A, Building 2, No. 699 Malu Avenue, Banan District, Chongqing
  • Website: https://www.genrixbio.com/
  • Company Profile: On November 26, 2021, ShineWing Certified Public Accountants (Special General Partnership) issued the audit report XYZH/2021BJAA110953. As of September 30, 2021, the net assets of Zhixiang Limited were 391.9364 million RMB. On November 26, 2021, Beijing Zhongtonghua Asset Appraisal Co., Ltd. issued the asset appraisal report Zhongtonghua Ping Bao Zi (2021) No. 011777. As of the appraisal base date September 30, 2021, the book value of Zhixiang Limited's net assets was 391.9364 million RMB, and the appraisal result of net assets was 476.5390 million RMB. On December 13, 2021, Zhixiang Limited held a shareholders' meeting and passed a resolution agreeing to convert Zhixiang Limited entirely into a joint stock limited company with all shareholders of Zhixiang Limited as the promoters. All promoters converted the audited net assets of Zhixiang Limited, 391.9364 million RMB, into 275 million shares at a ratio of 1:0.7016444. The original shareholders of Zhixiang Limited subscribed for shares with the net assets corresponding to their respective shareholding ratios in Zhixiang Limited. On December 13, 2021, all shareholders of Zhixiang Limited signed the "Sponsor Agreement for Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd. (Preparation)" and unanimously agreed to convert Zhixiang Limited entirely into a joint stock limited company. On December 14, 2021, the company held its founding meeting and the first interim shareholders' meeting of 2021, reviewing and passing relevant proposals including the "Proposal on the Establishment of Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd.", agreeing to convert Zhixiang Limited entirely into a joint stock limited company. On January 11, 2022, ShineWing Certified Public Accountants (Special General Partnership) issued the capital verification report XYZH/2022BJAA110065, verifying that as of December 17, 2021, the company had received the registered capital of 275 million RMB paid by all promoters. On December 17, 2021, the Chongqing Market Supervision Administration issued the "Business License" to the company. Unified Social Credit Code: 91500113MA5U36LJ53.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund Class A Fund 408.65 3.50
2 Shanghai Xinxi Investment Management Co., Ltd. - Shenzhen Xinxi Fuxing Investment Partnership (Limited Partnership) Corporate 333.33 2.86
3 Shenzhen Oriental Fortune Sea Venture Capital Management Co., Ltd. - Shenzhen Fuhai Junyong No. 4 Venture Capital Enterprise (Limited Partnership) Corporate 320.84 2.75
4 Fullgoal Enhanced Bond Securities Investment Fund Class A Fund 300.00 2.57
5 Haitong Innovation Securities Investment Co., Ltd. Securities Firm 292.15 2.50
6 Penghua Pharmaceutical Technology Equity Securities Investment Fund Class A Fund 283.29 2.43
7 Hong Kong Securities Clearing Company Ltd. Northbound Capital 196.00 1.68
8 Orient Securities (Hong Kong) Medical Upgrade Equity Initiated Securities Investment Fund Class A Fund 169.24 1.45
9 Beijing Langzi Hana Asset Management Co., Ltd. - Chengdu Gaotou Langhan Health Industry Partnership (Limited Partnership) Asset Management Plan 137.50 1.18
10 China Southern China Securities 1000 Exchange Traded Open-End Index Securities Investment Fund Fund 133.90 1.15

5. Concept Sectors

  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Loss-Making Stocks
  • Heavily Held by Securities Firms
  • Consecutive Losses
  • Below IPO Price
  • Fund Reduction
  • STAR Market Growth Layer
  • STAR Market Biotech
  • STAR Market Growth
  • STAR 100
  • SSE 580

Remarks

  • Data update date: 2025-11-01
  • Data source: Public Market Information